The Latest Breaking News from Madhav Vasanthavada

Abeona Therapeutics Q1 Earnings Call Highlights

Abeona Therapeutics (NASDAQ:ABEO) reported early commercial momentum for ZEVASKYN in the first quarter of 2026, with executives highlighting new patient treatments, expanded treatment-center activation and a newly licensed prostate cancer cell therapy program during the company’s earnings call. Chi

MarketBeat · May 13